The high baseline levels of AFP (> 20 ng/mL) may not be related to the initial therapy response, but several studies have reported that the AFP decline was associated with treatment response and significantly improved median survival in intermediate-stage HCC after TACE therapy (32–34). This evidence concerns the gene AFP and hepatocellular carcinoma.